Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
Open Access
- 20 August 2015
- journal article
- Published by American Society of Hematology in Blood
- Vol. 126 (8), 1009-1016
- https://doi.org/10.1182/blood-2014-12-614743
Abstract
Key Points 2-CdA is an effective treatment with a long-term acceptable safety profile in patients with mastocytosis. 2-CdA is effective and safe in indolent systemic mastocytosis and cutaneous mastocytosis refractory to multiple symptomatic therapies.Keywords
This publication has 27 references indexed in Scilit:
- Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 TrialBlood, 2014
- Tyrosine kinase inhibitors in the treatment of systemic mastocytosisLeukemia Research, 2011
- In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816VExperimental Hematology, 2010
- Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literatureCurrent Opinion in Hematology, 2010
- Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosineAmerican Journal of Hematology, 2009
- Thalidomide in advanced mastocytosisBritish Journal of Haematology, 2008
- A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.Blood, 2006
- Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosisBlood, 2006
- 2-Chlorodeoxyadenosine Therapy for Disseminated Langerhans Cell HistiocytosisMayo Clinic Proceedings, 2003
- Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patientsBritish Journal of Haematology, 2002